Connexios is an innovation driven, early stage drug discovery and development company focused on developing therapies that address the cellular pathology underlying metabolic diseases - namely, Type 2 Diabetes (T2D) and Non Alcoholic Steatohepatitis (NASH) leading to Chronic Liver Disease.
Guided by a unique Network Biology approach and platform, we have constructed an integrated molecular network view of these complex diseases at the cellular level in multiple tissues. This integrated view has helped us in the identification of “core” molecular mechanisms that drive the pathology at the cellular level across multiple tissues in these diseases. Our drug discovery strategy is focused on developing a diversified pipeline of novel chemical entities (NCE’s) based therapies that systemically target and modulate these core mechanisms across multiple tissues. Our pre-clinical pipeline is based on both completely novel as well as recently uncovered targets, where we have been able to significantly enrich the understanding of target biology and action using our Network Biology platform to develop highly differentiated therapies.
Our broad and innovative pipeline by targeting the core mechanisms underlying these diseases will translate into novel therapies that will significantly address the large set of unmet needs in the treatment of these global diseases that are assuming epidemic proportions.
Connexios has a highly experienced board, a large multi-disciplinary team of scientists (ranging from basic disease biology to pre-clinical development), comprehensive drug discovery and development capabilities, laboratory infrastructure located in Bengaluru, India. Connexios is funded privately.